Explore
Trendline
EyePoint Reports Q1 2026 Financial Results, Highlights Progress in Retinal Disease Trials
EyePoint Reports Q1 2026 Financial Results, Highlights Progress in Retinal Disease Trials
Read More
Trendline
EyePoint Reports Q1 2026 Financial Results and Advances in Retinal Disease Therapies
EyePoint Reports Q1 2026 Financial Results and Advances in Retinal Disease Therapies
Read More
Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026
Nuvectis Pharma Reports Increased Net Loss in Q1 2026
Read More
Trendline
EyePoint Inc. Reports Increased Losses Amid Phase 3 Clinical Trials Funding
EyePoint Inc. Reports Increased Losses Amid Phase 3 Clinical Trials Funding
Read More
Trendline
EyePoint Reports Increased Losses Amid DURAVYU Phase 3 Trials Progress
EyePoint Reports Increased Losses Amid DURAVYU Phase 3 Trials Progress
Read More
Trendline
Exelixis Reports Q1 2026 Financial Results and Announces New Drug Developments
Exelixis Reports Q1 2026 Financial Results and Announces New Drug Developments
Read More
Trendline
Vanda Pharmaceuticals Reports Q1 2026 Financial Results Highlighting Growth and New Product Launches
Vanda Pharmaceuticals Reports Q1 2026 Financial Results Highlighting Growth and New Product Launches
Read More
Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Expansion Plans
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Expansion Plans
Read More
Trendline
Bruker Corporation Reports Q1 2026 Financial Results with Revenue Growth
Bruker Corporation Reports Q1 2026 Financial Results with Revenue Growth
Read More
Trendline
Contineum Therapeutics Reports Q1 2026 Financial Results and Clinical Milestones
Contineum Therapeutics Reports Q1 2026 Financial Results and Clinical Milestones
Read More
Trendline
ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates
ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates
Read More
Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Read More
